# Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

> **NCT00806208** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 34 (actual)

## Conditions studied

- Graft-Versus-Host Disease

## Interventions

- **DRUG:** MEDI-507
- **DRUG:** MEDI-507
- **DRUG:** MEDI-507
- **DRUG:** MEDI-507
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00806208
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2000-01
- **Final completion:** 2000-03
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2008-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806208, "Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00806208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*